Iyshwarya Balasubramanian

Background: _LRRK2_ variants (G2019S/N2081D) that increase Parkinson’s disease (PD) and Crohn’s Disease (CD) susceptibility are associated with LRRK2 kinase hyperactivity and suppress autophagy, suggesting that LRRK2 kinase inhibition, a strategy being explored for PD treatment, may also benefit CD…